Daclizumab to Treat Wegener's Granulomatosis

NCT00040248 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

NIH

Sponsor class

Conditions

Wegener's Granulomatosis

Interventions

DRUG: Daclizumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)